Lab for Home 1

Pipeline Opportunities in the Clinic for Fibrosis and Inflammation

Pan-LOX inhibitor PXS-5505

  • Targeting liver and pancreatic cancer
  • Status: protocol and funding discussions with independent investigators
  • More information here

LOXL2 inhibitor PXS-5382

  • Anti fibrotic targeting chronic kidney disease (CKD), pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH)
  • Status: Partnering discussions for phase 2 commencement
  • More information here

Topical pan-LOX inhibitor PXS-6302

  • Anti scarring: burns, established scars
  • Status: Phase 1 Investigator Initiated Studies (IIS) commenced Q1 2021 (read more here); IIS patient studies in burns and established scars H2 2021
  • More information here

SSAO inhibitor PXS-4728

  • Anti inflammatory: neuro inflammation
  • Status: Evaluate Boehringer data package and the opportunity to repurpose
  • More information here
Home page WJ and DH

Pharmaxis Targets Myelofibrosis in New Clinical Trial

Pharmaxis is advancing a 6-month Phase 2 clinical trial of a new drug (PXS-5505) targeting the rare bone cancer myelofibrosis (MF).

PXS-5505 is an anti‐fibrotic pan-Lysyl Oxidase (pan-LOX) inhibitor that has completed long-term toxicity studies and Phase 1a and 1b clinical trials demonstrating a well-tolerated drug that effectively inhibits all enzymes in the lysyl oxidase family that are involved in fibrosis.

Myelofibrosis is a cancer with a poor prognosis and limited therapeutic options. Pharmaxis believes that the current treatments can be augmented by use of a pan-LOX inhibitor and be disease modifying in a market that is conservatively worth US$1 billion per annum.

PXS-5505 was granted Orphan Drug Designation by the US Food and Drug Administration (FDA) in July 2020. Read the media release.

In August 2020 the FDA completed a review of the company’s Investigational New Drug (IND) application for PXS-5505 and gave Pharmaxis the green light to proceed with a phase 1c/2a clinical trial for the treatment of myelofibrosis in adults.  The clinical trial protocol incorporates a one-month dose escalation phase followed by six months’ treatment in an open label study of patients who are not on a JAK inhibitor. The first patient was enrolled in Q1 2021 and the study is expected to conclude in 2022. Read the media release.

A study published by researchers at Boston University School of Medicine has found that the two Pharmaxis drug discoveries PXS-LOX_1 and PXS-LOX_2 are showing promising early results in slowing disease progression in primary myelofibrosis (PMF). Read more here:

Gary Phillips CEO Pharmaxis

Recent News

Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars

A Pharmaxis drug discovery has entered a world first clinical trial aiming to stop scars forming after trauma, particularly following burn injuries.

The company is collaborating with renown burns specialist Prof Fiona Wood and a team at the University of Western Australia to tackle the underlying fibrosis causing scar tissue.  

Pre-clinical tests on the Pharmaxis compound PXS-6302 have shown promising results and studies have now progressed to humans.

Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on patients. 

Read the media release here.

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Pharmaxis Ltd has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis.

Read the media release here.

Pharmaxis Starts Exporting Its Cystic Fibrosis Drug to The USA Following FDA Approval

  • US$3 million milestone payment triggered
  • Manufactured and packaged by Pharmaxis in Australia
Read the media release here.

Pharmaxis Quarterly Shareholder Update - December 2020

Read the update here.

Current Investor Presentation

 View here

Recent interviews and articles: 

Pharmaxis Investment Summary available here